← brief for 2026-08-18 · Slowing decline

Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors in chronic kidney disease: an updated meta-analysis.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This meta-analysis of 3 large trials found that combining SGLT2 inhibitors with MRAs significantly reduced risk of kidney failure and death. The benefit was consistent across different-sized trials.

Who did this work

Kamido H · Hasebe M · Su CY · Sawa N · Yoshiji S

Source

Article · PubMed, the drug frontier · 2026 Aug 18
https://pubmed.ncbi.nlm.nih.gov/42610389/